Categories AlphaGraphs, Earnings

Amgen profit jumps on strong product sales, tops estimates

Benefitting from broad-based growth in product sales and lower tax rate, Amgen’s (AMGN) first-quarter earnings increased from last year and came in above forecast. The impressive results come at a time when the drug industry is facing pricing pressure from a new government regulation.

Following the announcement, shares of the biotech company gained modestly in the afterhours, paring a part of the loss they suffered during the regular session.

First quarter profit climbed 16% year-on-year to $3.25 per share, driven by double-digit sales growth across all product categories and a decline in tax rate. Earnings, excluding one-time items, advanced 10% to $3.47 per share.

Amgen Q1 2018 Earnings

Helped by the strong product sales, revenues increased 1.6% to $5.55 billion during the three-month period, surpassing market expectations.

“Amgen’s strong first-quarter performance was driven by our new and recently launched products, all of which delivered double-digit, volume-driven growth,” said Amgen CEO Robert Bradway.

Looking ahead, the Thousand Oaks, California-based company revised its EPS outlook for fiscal 2018 to the range of $11.30 to $12.28. Full-year adjusted earnings are currently expected to be between $12.80 per share and $13.70 per share. The revenue outlook was revised to $21.9 billion to $22.8 billion. The mid-point of the guidance is below analysts’ projection.

Helped by the strong product sales, revenues increased 1.6% to $5.55 billion during the three-month period, surpassing market expectations.

Quarterly results published by leading biotech and drug firms recently indicate the sector is emerging from a period of volatility, owing to the market pressure induced by the trade war concerns.  Of late, a sector-wide squeeze on product prices has resulted in the pharma index of S&P 500 falling around 5% since the beginning of the year.

Amgen’s competitor Johnson & Johnson (JNJ) last week reported a 13% rise in first-quarter adjusted earnings to $2.06 per share. The core earnings of Novartis (NVS) climbed to $1.28 per share in the first quarter from $1.13 per share a year earlier. Results of both J&J and Novartis topped estimates. Merck & Company (MRK) will be publishing its first-quarter results on May 1.

Most Popular

HPE Earnings: Hewlett Packard Q1 2024 profit drops but beats Street view

Information technology solutions provider Hewlett Packard Enterprise (NYSE: HPE) on Thursday reported lower earnings and revenues for the first quarter of 2024. Earnings, however, exceeded analysts’ forecasts. First-quarter profit, excluding

After entering FY24 on a high note, Costco is all set to report Q2 results

Costco Wholesale Corporation (NASDAQ: COST) stands out in the retail space for its unique business model that enables the warehouse behemoth to grow store traffic and market share constantly. Currently,

Hormel (HRL) expects continued momentum from its foodservice business in FY2024

Shares of Hormel Foods Corporation (NYSE: HRL) soared over 13% on Thursday after the company delivered better-than-expected earnings results for the first quarter of 2024 and reaffirmed its outlook for

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top